Qualifying Therapeutic Discovery Project Grants for the State of Missouri
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Antigen Laboratories, Inc | Sublingual CAT Hair Allergenic Extract | $ 244,479.25 | |
| APT Therapeutics, Inc. | Therapeutic Use of Human Apyrase | $ 244,479.25 | |
| BioMed Valley Discoveries Inc | Combination Bacteriolytic Therapy {COLBALT} Project | $ 6,403.00 | $ 178,957.50 |
| BioMed Valley Discoveries, Inc | Phenix Inflammation Project | $ 244,479.25 | |
| BioMed Valley Discoveries, Inc. | In Vivo FIAU Project | $ 69,601.00 | $ 174,878.25 |
| BioMed Valley Discoveries, Inc. | Phenix Chagas Project | $ 43,688.50 | $ 72,998.00 |
| BioMed Valley Discoveries, Inc. | Phenix Diabetes Project | $ 116,561.50 | $ 127,917.75 |
| CardiaLen, Inc. | Low-Energy Atrial Cardioverter | $ 42,532.00 | $ 188,481.00 |
| Daya Drug Discoveries Inc | Novel Serotonin Agonists/Antagonists for the Treatment of Neurological Disorders | $ 83,759.00 | $ 102,600.00 |
| Daya Drug Discoveries Inc | Small Molecule Steriod Mimics for Molecular Imaging and Therapy of Breast Cancers | $ 20,000.00 | |
| ENDOSTIM INC | ENDOSTIM MICROSTIMULATOR | $ 152,091.15 | $ 92,388.10 |
| Evogen, Inc | Fully automated point of care platform for the diagnosis of infectious disease and genotyping | $ 244,479.25 | |
| Foundation Care LLC | Cystic Fibrosis Health Management Program | $ 110,000.00 | $ 134,479.24 |
| Galera Therapeutics LLC | Development of a Drug to Prevent Oral Mucositis in Cancer Patients | $ 244,479.25 | |
| Gerhard W. Cibis, M.D., P.C. | Automated Video Vision Development Assessment (AVVDA) | $ 46,300.50 | $ 44,000.00 |
| Immunophotonics, Inc | Laser-Assisted Immunotherapy | $ 7,821.54 | $ 236,657.71 |
| ISTO Technologies Inc | Cell-based technology platform | $ 244,479.25 | |
| Kereos, Inc | Molecularly Targeted Nanostructures for Anticancer Therapy with Cytologic Peptides | $ 88,108.50 | $ 66,696.50 |
| Kereos, Inc | Development of a F-19 Imaging Agent for Early Diagnosis of Cancer and Cardiovascular Disease | $ 162,045.00 | $ 82,434.24 |
| LipoSpectrum LLC | Multi-Dimensional Mass Spectrometry-based Shotgun Lipidomics (MDMS-SL) | $ 90,860.00 | $ 95,111.00 |
| Mediomics LLC | Molecular PINCER-based biosensors for point of care diagnosis | $ 244,479.24 | |
| Mobius Therapeutics, LLC | Optomycin | $ 230,779.50 | $ 13,699.74 |
| Pepex Biomedical | Composite Conductive Monofilament (CCM) Biosensor Technology- Therapeutic Applications | $ 244,479.25 | |
| Sequoia Sciences, Inc. | Novel therapeutic vaccine for urinary tract infections | $ 159,106.63 | $ 85,372.61 |
| Sequoia Sciences, Inc. | Novel Small Molecule Therapeutic for the Treatment of Recalcitrant Bacterial Infections | $ 244,479.25 | |
| Shear Kershman Laboratories | A Tamper Resistant Delivery System for Opiods | $ 16,408.50 | $ 95,420.10 |
| Stereotaxis, Inc | V-Drive | $ 244,479.25 | |
| Stereotaxis, Inc | TOTAR | $ 40,750.00 | $ 74,000.00 |
| Stereotaxis, Inc | STOP-VT | $ 20,580.00 | $ 101,804.00 |
| Stereotaxis, Inc. | Navigant 3.2 | $ 244,479.25 | |
| Stereotaxis, Inc. | Vascular Remote Advancement Systems (VRAS) and Next Gen Radiofrequency Generator | $ 209,745.50 | $ 34,733.75 |
| Stereotaxis, Inc. | Odyssey | $ 244,479.25 | |
| Stererotaxis, Inc | Next Generation Catheters | $ 120,134.00 | $ 124,345.25 |
| Traxxsson, LLC | Biomarkers for Diagnosis and Prognosis of Cancer | $ 21,947.00 | $ 41,950.00 |
| Veran Medical Technologies, Inc | SPiN Drive | $ 244,479.25 | |
| VirRx Inc | Cancer Therapy with Oncolytic Adenovirus VRX-007 | $ 244,479.25 | |
| ZeaVision LLC | Macular Pigment Reflectometer (MPR) | $ 55,852.50 | $ 188,626.74 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
